Soma Pharmacy Blognews

FDA Panel OKs HPV Vaccine Gardasil for Boys An FDA advisory committee today voted to recommend approving the vaccine Gardasil for males ages 9 to 26 to prevent genital warts.

Businesses Wary of Severe Swine Flu A new survey shows that most U.S. businesses are concerned that swine flu will have a negative effect on business if cases are widespread and severe this fall and winter.

Home-Cooked Meals Put on the Backburner Job stress and irregular working hours are recipes for more fast food, less time at the dinner table, and more skipped meals, a new study suggests.

Report Stirs Debate on Cell Phone Safety Recent scientific studies linking cell phone use with health effects such as brain cancer are showing increasing evidence of harm, according to a report by the Environmental Working Group (EWG), a public health advocacy group based in Washington, D.C.

Advanced Gum Disease May Raise Cancer Risk A new study suggests a common form of gum disease may significantly raise the risk of head and neck cancer.

ARUP Laboratories’ scientist receives grant to research HIV therapies ARUP Laboratories, a national clinical and anatomic pathology reference laboratory and a leader in innovative laboratory research and development, announced that ARUP’s Tanya Sandrock, PhD, Research & Development scientist, received a prestigious National Institutes of Health (NIH) grant to research additional HIV therapies.

Chemgenex completes NDA submission for its omacetaxine mepesuccinate to the FDA ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today the completion of its New Drug Application (NDA) submission to the U.S. Food & Drug Administration (FDA) for OMAPRO™ (omacetaxine mepesuccinate). OMAPRO™ is being developed for the treatment of patients with chronic myeloid leukemia (CML) who have failed [...]

Caldolor launched ahead of schedule in U.S. by Cumberland Pharmaceuticals Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) announced today that it has successfully implemented the U.S. launch of Caldolor((R)), an intravenous formulation of ibuprofen, designed primarily for use in the hospital setting.

HCV treatment study reveals low relapse rate of Pegetron Recently published in the New England Journal of Medicine, the largest prospective study of chronic hepatitis C virus (HCV) treatments Pegetron and Pegasys RBV (R) found both treatments equal in achieving sustained viral response. The study also found that Pegetron had a significantly lower relapse rate [...]

Updated third-quarter 2009 report on the Belarus pharmaceuticals and healthcare industry Research and Markets (http://www.researchandmarkets.com/research/331332/belarus_pharmaceut) has announced the addition of the “Belarus Pharmaceuticals and Healthcare Report Q3 2009″ report to their offering.